Close Menu

NEW YORK (GenomeWeb) – Invivoscribe announced today that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved the firm's LeukoStrat CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo's quizartinib for the treatment of FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML) patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.